Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Wang, Wenshi ^a   Yu, Daohai ^a   Sarnaik, Amod A ^a   Yu, Bin ^a   Hall, Maclean ^a   Morelli, Dawn ^a   Zhang, Yonghong ^a   Zhao, Xiuhua ^a   Weber, Jeffrey S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Antibody; Biomarker; CTLA 4; Melanoma

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR7; GRANZYME B; INTERLEUKIN 2 RECEPTOR ALPHA; IPILIMUMAB; KI 67 ANTIGEN; TRANSCRIPTION FACTOR GATA 3;

ARTICLE; CANCER RECURRENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; INTRACELLULAR SIGNALING; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; MALE; MELANOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL;

EID: 84863672266     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-146     Document Type: Article

References (48)

1. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nature Reviews. Cancer 2007, 7:95-106. 10.1038/nrc2051, 17251916.
2. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annual Review of Immunology 2001, 19:565-594. 10.1146/annurev.immunol.19.1.565, 11244047.
3. Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH. CTLA-4 regulates induction of anergy in vivo. Immunity 2001, 14:145-155. 10.1016/S1074-7613(01)00097-8, 11239447.
4. Schneider H, Valk E, Leung R, Rudd CE. CTLA-4 activation of phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB/AKT) sustains T-cell anergy without cell death. PLoS One 2008, 3:e3842. 10.1371/journal.pone.0003842, 2585791, 19052636.
5. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 2002, 16:23-35. 10.1016/S1074-7613(01)00259-X, 11825563.
6. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nature Immunology 2002, 3:611-618. 10.1038/ni0702-611, 12087419.
7. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736. 10.1126/science.271.5256.1734, 8596936.
8. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. The Journal of Clinical Investigation 2006, 116:1935-1945. 10.1172/JCI27745, 1479425, 16778987.
9. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992, 71:1093-1102. 10.1016/S0092-8674(05)80059-5, 1335364.
10. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. The Journal of Experimental Medicine 1999, 190:355-366. 10.1084/jem.190.3.355, 2195583, 10430624.
11. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511. 10.1038/nature01621, 12724780.
12. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270:985-988. 10.1126/science.270.5238.985, 7481803.
13. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. The Oncologist 2008, 13(Suppl 4):2-9.
14. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. Journal of Immunology 2005, 175:7746-7754.
15. Ribas A. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). The Oncologist 2008, 13(Suppl 4):10-15.
16. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. The Lancet Oncology 2011, 11(2):155-164.
17. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clinical Cancer Research 2009, 15:5591-5598. 10.1158/1078-0432.CCR-09-1024, 19671877.
18. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunology, Immunotherapy 2009, 58:823-830. 10.1007/s00262-008-0653-8, 19198837.
19. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. Journal of Clinical Oncology 2008, 26:5275-5283. 10.1200/JCO.2008.17.8954, 18838703.
20. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003, 100:8372-8377. 10.1073/pnas.1533209100, 166236, 12826605.
21. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Annals of Oncology 2010, 21(8):1712-1717. 10.1093/annonc/mdq013, 20147741.
22. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. mproved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010, 363:711-723. 10.1056/NEJMoa1003466, 20525992.
23. Robert C, Thomas L, Bondarenko I, O'Day S, DJ M, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine 2011, 364:2517-2526. 10.1056/NEJMoa1104621, 21639810.
24. Yuan J, Page DB, Ku GY, Li Y, Mu Z, Ariyan C, et al. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immunity 2010, 10:1-7. 2964016, 20052966.
25. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. Journal of Clinical Oncology 2005, 23:741-750. 10.1200/JCO.2005.01.128, 15613700.
26. Sarnaik AA, Yu B, Yu D, Morelli DR, Hall MS, Bogle D, et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clinical Cancer Research 2011, 17(4):896-906. 10.1158/1078-0432.CCR-10-2463, 3041838, 21106722.
27. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clinical Cancer Research 16:2861-2871.
28. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, et al. Anti-CTLA-4 therapy results in higher CD4 + ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA 2009, 106:2729-2734. 10.1073/pnas.0813175106, 2650334, 19202079.
29. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. Journal of Clinical Oncology 2005, 23:6043-6053. 10.1200/JCO.2005.06.205, 1473965, 16087944.
30. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clinical Cancer Research 2009, 15:390-399. 10.1158/1078-0432.CCR-08-0783, 19118070.
31. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. Journal of Translational Medicine 2009, 7:35. 10.1186/1479-5876-7-35, 2697137, 19457253.
32. Comin-Anduix B, Sazegar H, Chodon T, Matsunaga D, Jalil J, von Euw E, et al. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One 2010, 5:e12711. 10.1371/journal.pone.0012711, 2939876, 20856802.
33. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, et al. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. Journal of Nuclear Medicine 2010, 51:340-346. 10.2967/jnumed.109.070946, 20150263.
34. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clinical Cancer Research 2011, 17:4101-4109. 10.1158/1078-0432.CCR-11-0407, 3117971, 21558401.
35. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA 1990, 87:1663-1667. 10.1073/pnas.87.5.1663, 53542, 1689846.
36. Liu WM, Mei R, Di X, Ryder TB, Hubbell E, Dee S, et al. Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics 2002, 18:1593-1599. 10.1093/bioinformatics/18.12.1593, 12490443.
37. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Research 2003, 31:e15. 10.1093/nar/gng015, 150247, 12582260.
38. Strimmer K. fdrtool: a versatile R package for estimating local and tail area-based false discovery rates. Bioinformatics 2008, 24:1461-1462. 10.1093/bioinformatics/btn209, 18441000.
39. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. Journal of Cellular Physiology 2000, 182:311-322. 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9, 10653597.
40. Hertoghs KM, Moerland PD, van Stijn A, Remmerswaal EB, Yong SL, van de Berg PJ, et al. Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation. The Journal of Clinical Investigation 2010, 120:4077-4090. 10.1172/JCI42758, 2964975, 20921622.
41. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001, 409:97-101. 10.1038/35051100, 11343121.
42. McAdam AJ, Chang TT, Lumelsky AE, Greenfield EA, Boussiotis VA, Duke-Cohan JS, et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol 2000, 165:5035-5040.
43. Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, et al. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 2003, 302:1041-1043. 10.1126/science.1090148, 14605368.
44. Bauquet AT, Jin H, Paterson AM, Mitsdoerffer M, Ho IC, Sharpe AH, et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nature Immunology 2009, 10:167-175. 10.1038/ni.1690, 2742982, 19098919.
45. Fu T, He Q, Sharma P. The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy. Cancer Research 2011, 71:5445-5454. 10.1158/0008-5472.CAN-11-1138, 21708958.
46. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clinical Cancer Research 2009, 15:6267-6276. 10.1158/1078-0432.CCR-09-1254, 2765061, 19789309.
47. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007, 4:e176. 10.1371/journal.pmed.0040176, 1865558, 17488182.
48. Rudd CE. CTLA-4 co-receptor impacts on the function of Treg and CD8+ T-cell subsets. Eur J Immunol 2009, 39:687-690. 10.1002/eji.200939261, 19283722.